Public-registry site landscape for NCT05207722, a Metastatic HER2 Positive Gastroesophageal Junction Cancer study sponsored by Celularity Incorporated. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05207722 (registry record) |
| Sponsor | Celularity Incorporated |
| Condition(s) | Metastatic HER2 Positive Gastroesophageal Junction Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 3 |
| Site countries | United States |
Eichor generates a preliminary site-risk snapshot for NCT05207722 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →